130 related articles for article (PubMed ID: 37028695)
1. Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease.
Perros P; Žarković M; Pearce SH; Razvi S; Kolli H; Dickinson AJ
Am J Ophthalmol; 2023 Aug; 252():94-100. PubMed ID: 37028695
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.
Ko J; Kook KH; Yoon JS; Woo KI; Yang JW;
BMJ Open; 2022 Jun; 12(6):e050337. PubMed ID: 35728893
[TBL] [Abstract][Full Text] [Related]
3. Novel thermal imaging analysis technique for detecting inflammation in thyroid eye disease.
Di Maria C; Allen J; Dickinson J; Neoh C; Perros P
J Clin Endocrinol Metab; 2014 Dec; 99(12):4600-6. PubMed ID: 25238202
[TBL] [Abstract][Full Text] [Related]
4. Natural history of inflammatory and non-inflammatory dry eye in thyroid eye disease.
Lo C; Yang M; Rootman D
Orbit; 2021 Oct; 40(5):389-393. PubMed ID: 32847459
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory and Noninflammatory Thyroid Eye Disease: Comparison of Disease Signs, Symptoms, and Quality of Life in Patients in the United States.
Wang Y; Padnick-Silver L; Francis-Sedlak M; Holt RJ; Foley C; Douglas RS
Endocr Pract; 2022 Sep; 28(9):842-846. PubMed ID: 35714862
[TBL] [Abstract][Full Text] [Related]
6. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
7. Soft Tissue Metrics in Thyroid Eye Disease: An International Thyroid Eye Disease Society Reliability Study.
Mawn LA; Dolman PJ; Kazim M; Strianese D; Genol I; Chong KKL; Sullivan TJ; Korn BS; Naik M; Dutton J; Velasco E Cruz A; Li C
Ophthalmic Plast Reconstr Surg; 2018; 34(6):544-546. PubMed ID: 29465482
[TBL] [Abstract][Full Text] [Related]
8. Teprotumumab for chronic thyroid eye disease.
Ozzello DJ; Dallalzadeh LO; Liu CY
Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
[TBL] [Abstract][Full Text] [Related]
9. Demographic and clinical profile of 1000 patients with thyroid eye disease presenting to a Tertiary Eye Care Institute in India.
Naik MN; Vasanthapuram VH
Int Ophthalmol; 2021 Jan; 41(1):231-236. PubMed ID: 32844239
[TBL] [Abstract][Full Text] [Related]
10. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease.
Mayer EJ; Fox DL; Herdman G; Hsuan J; Kabala J; Goddard P; Potts MJ; Lee RW
Eur J Radiol; 2005 Oct; 56(1):20-4. PubMed ID: 15896938
[TBL] [Abstract][Full Text] [Related]
11. Thyroid eye disease presenting with superior rectus/levator complex enlargement.
Wang Y; Mettu P; Broadbent T; Radke P; Firl K; Shepherd JB; Couch SM; Nguyen A; Henderson AD; McCulley T; McClelland CM; Mokhtarzadeh A; Lee MS; Garrity JA; Harrison AR
Orbit; 2020 Feb; 39(1):5-12. PubMed ID: 31056988
[No Abstract] [Full Text] [Related]
12. Choroidal vascularity index in thyroid eye disease: comparison with controls and application in diagnosing non-inflammatory active disease.
Dave TV; Jonnadula GB; Lanka P; Natarajan R; Dave VP
Orbit; 2022 Feb; 41(1):89-96. PubMed ID: 34979862
[TBL] [Abstract][Full Text] [Related]
13. Low dose orbital radiotherapy for thyroid eye disease.
Li Yim JF; Sandinha T; Kerr JM; Ritchie D; Kemp EG
Orbit; 2011 Dec; 30(6):269-74. PubMed ID: 22132844
[TBL] [Abstract][Full Text] [Related]
14. Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy.
Edmunds MR; Boelaert K
Thyroid; 2019 Apr; 29(4):557-562. PubMed ID: 30688164
[TBL] [Abstract][Full Text] [Related]
15. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.
Mourits MP; Prummel MF; Wiersinga WM; Koornneef L
Clin Endocrinol (Oxf); 1997 Jul; 47(1):9-14. PubMed ID: 9302365
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in clinical presentation and prognosis of thyroid eye disease.
Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Ben Simon G
Eur J Ophthalmol; 2021 Sep; 31(5):2717-2723. PubMed ID: 33158379
[TBL] [Abstract][Full Text] [Related]
17. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach.
Douglas RS; Kossler AL; Abrams J; Briceño CA; Gay D; Harrison A; Lee M; Nguyen J; Joseph SS; Schlachter D; Tan J; Lynch J; Oliver L; Perry R; Ugradar S
J Neuroophthalmol; 2022 Sep; 42(3):334-339. PubMed ID: 35421877
[TBL] [Abstract][Full Text] [Related]
18. The function and morphology of Meibomian glands in patients with thyroid eye disease: a preliminary study.
Wang CY; Ho RW; Fang PC; Yu HJ; Chien CC; Hsiao CC; Kuo MT
BMC Ophthalmol; 2018 Apr; 18(1):90. PubMed ID: 29649988
[TBL] [Abstract][Full Text] [Related]
19. A Multidisciplinary Thyroid Eye Clinic: A One-stop Shop.
Zloto O; Sagiv O; Priel A; Cukierman-Yaffe T; Tirosh A; Agmon-Levin N; Madgar S; Serlin T; Winter H; Huna-Baron R; Wygnanski-Jaffe T; Ben Simon G
Isr Med Assoc J; 2022 Oct; 24(10):671-676. PubMed ID: 36309864
[TBL] [Abstract][Full Text] [Related]
20. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
Xu N; Cui Y; Fu D; Sun F
J Endocrinol Invest; 2020 Jul; 43(7):901-910. PubMed ID: 31927748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
